These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 14669540

  • 1. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ, Lokhorst HL, Verdonck LF.
    Ned Tijdschr Geneeskd; 2003 Nov 22; 147(47):2328-32. PubMed ID: 14669540
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 22; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
    Görner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F, Punzel M, Weber-Nordt R, Moos M, Goldschmidt H, Ho AD.
    Bone Marrow Transplant; 2002 Apr 22; 29(7):621-4. PubMed ID: 11979314
    [Abstract] [Full Text] [Related]

  • 4. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Apr 22; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

  • 5. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.
    Bone Marrow Transplant; 2001 Sep 22; 28(6):557-62. PubMed ID: 11607768
    [Abstract] [Full Text] [Related]

  • 6. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.
    Am J Hematol; 2007 Oct 22; 82(10):873-80. PubMed ID: 17570513
    [Abstract] [Full Text] [Related]

  • 7. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 22; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 8. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J.
    Bone Marrow Transplant; 2003 Jul 22; 32(1):9-13. PubMed ID: 12815472
    [Abstract] [Full Text] [Related]

  • 9. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M.
    Dtsch Med Wochenschr; 2005 Sep 23; 130(38):2125-9. PubMed ID: 16172951
    [Abstract] [Full Text] [Related]

  • 10. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 Sep 23; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 11. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG, Ullmann AJ, Huber C, Kolbe K, Herr W.
    Ann Hematol; 2005 May 23; 84(5):331-8. PubMed ID: 15726363
    [Abstract] [Full Text] [Related]

  • 12. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 23; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 13. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM, Lerma E, Dejana A, Corsetti MT, Celesti L, Bruni R, Benvenuto F, Figari O, Parodi C, Carlier P, Florio G, Lercari G, Valbonesi M, Casarino L, De Stefano F, Geniram A, Venturino M, Tedeschi L, Palmieri G, Piaggio G, Podestà M, Frassoni F, Van Lint MT, Marmont AM, Bacigalupo A.
    Haematologica; 1998 Oct 23; 83(10):904-9. PubMed ID: 9830799
    [Abstract] [Full Text] [Related]

  • 14. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.
    Falda M, Busca A, Baldi I, Mordini N, Bruno B, Allione B, Rambaldi A, Morello E, Narni F, Santarone S, Locatelli F, Bacigalupo A, Gruppo Italiano Trapianto Midollo Osseo (GITMO).
    Am J Hematol; 2007 Oct 23; 82(10):863-6. PubMed ID: 17616972
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.
    Bone Marrow Transplant; 2007 Feb 23; 39(4):193-9. PubMed ID: 17220905
    [Abstract] [Full Text] [Related]

  • 16. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW, Schmidt-Hieber M, Leschinger N, Göldner H, Knauf W, Hopfenmüller W, Thiel E, Blau O.
    Ann Hematol; 2007 Aug 23; 86(8):583-9. PubMed ID: 17468869
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E, Landonio G, Locatelli F, Siena S, Della Cuna GR.
    Cancer; 2002 May 01; 94(9):2409-15. PubMed ID: 12015766
    [Abstract] [Full Text] [Related]

  • 18. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
    Biol Blood Marrow Transplant; 2003 Mar 01; 9(3):162-9. PubMed ID: 12652466
    [Abstract] [Full Text] [Related]

  • 19. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y, Labopin M, Hennequin C, Hoffstetter S, Mungai R, Wygoda M, Lundell M, Finke J, Aktinson C, Lorchel F, Durdux C, Basara N.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):544-51. PubMed ID: 17141976
    [Abstract] [Full Text] [Related]

  • 20. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, Niedzwiecki D, Dowell JM, Waters-Pick B, Liu C, Marshall D, Vredenburgh JJ, Gockerman J, Decastro C, Moore J, Chao NJ.
    J Clin Oncol; 2007 Feb 20; 25(6):690-7. PubMed ID: 17228020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.